Search This Blog

Wednesday, May 13, 2026

Tango advances vopimetostat toward pivotal MTAP-deleted pancreatic cancer development

 

Tango Therapeutics advances vopimetostat toward pivotal MTAP-deleted pancreatic cancer development as it posts Q1 2026 $45.5M net loss

  • Company disclosed changes to its board of directors in a new SEC filing today.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)